Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection

Sibylle Grub, Patricia DeLora, Eric Lüdin, Frank Duff, Courtney V Fletcher, Richard C. Brundage, Mark W. Kline, Nancy R. Calles, Heidi Schwarzwald, Karin Jorga

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: Our objective was to investigate the clinical pharmacologic characteristics of saquinavir given as a soft gelatin capsule, either alone or in combination with nelfinavir, to children and adolescents with human immunodeficiency virus infection. Methods: The pharmacokinetics of 50 mg/kg saquinavir 3 times a day (tid) alone versus 33 mg/kg saquinavir tid plus 30 mg/kg nelfinavir tid was assessed after single-dose administration and after short- and long-term administration. The single-dose pharmacokinetics of fixed (1200 mg) versus unrestricted weight-adjusted dosing (50 mg/kg) was also investigated. Results: Saquinavir as the sole protease inhibitor resulted in lower saquinavir exposure in children (steady-state geometric mean area under the concentration-time curve from time zero to 24 hours [AUC (0-24 h)], 5790 ng · h/ml; steady-state concentration 8 hours after drug administration [C8h,SS], 65 ng/ml) and adolescents [steady-state geometric mean AUC(0-24 h), 5914 ng · h/ml] than that reported in adults treated with 1200 mg tid [steady-state geometric mean AUC(0-24 h), 21,700 ng · h/ml; C8h,SS, 223 ng/ml]. This finding appeared to be attributable to markedly higher apparent oral clearance, potentially as a result of increased systemic clearance and reduced oral bioavailability. Nelfinavir combined with saquinavir reduced apparent oral clearance, increasing saquinavir exposure in children [steady-state geometric mean AUC(0-24 h), 11,070 ng · h/ml; C8h,SS, 380 ng/ml] to levels that approach those observed in adults. A significant correlation between average trough concentration and sustained viral load suppression was observed in children. The apparent threshold for maintaining viral load suppression was a mean trough saquinavir concentration above 200 ng/ml. Conclusions: The pharmacokinetics of saquinavir in children is different from that of adults, and administration of saquinavir alone will not give consistently efficacious plasma levels. The best way of improving saquinavir exposure in children is through combination therapy with other protease inhibitors that inhibit saquinavir metabolism.

Original languageEnglish (US)
Pages (from-to)122-130
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume71
Issue number3
DOIs
StatePublished - Apr 13 2002

Fingerprint

Saquinavir
Virus Diseases
Pharmacokinetics
HIV
Pediatrics
Nelfinavir
Area Under Curve
Protease Inhibitors
Viral Load
Gelatin
Biological Availability
Capsules

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. / Grub, Sibylle; DeLora, Patricia; Lüdin, Eric; Duff, Frank; Fletcher, Courtney V; Brundage, Richard C.; Kline, Mark W.; Calles, Nancy R.; Schwarzwald, Heidi; Jorga, Karin.

In: Clinical Pharmacology and Therapeutics, Vol. 71, No. 3, 13.04.2002, p. 122-130.

Research output: Contribution to journalArticle

Grub, S, DeLora, P, Lüdin, E, Duff, F, Fletcher, CV, Brundage, RC, Kline, MW, Calles, NR, Schwarzwald, H & Jorga, K 2002, 'Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection', Clinical Pharmacology and Therapeutics, vol. 71, no. 3, pp. 122-130. https://doi.org/10.1067/mcp.2002.121423
Grub, Sibylle ; DeLora, Patricia ; Lüdin, Eric ; Duff, Frank ; Fletcher, Courtney V ; Brundage, Richard C. ; Kline, Mark W. ; Calles, Nancy R. ; Schwarzwald, Heidi ; Jorga, Karin. / Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. In: Clinical Pharmacology and Therapeutics. 2002 ; Vol. 71, No. 3. pp. 122-130.
@article{21b2e2a2c0384402ae14e08783d798f4,
title = "Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection",
abstract = "Objective: Our objective was to investigate the clinical pharmacologic characteristics of saquinavir given as a soft gelatin capsule, either alone or in combination with nelfinavir, to children and adolescents with human immunodeficiency virus infection. Methods: The pharmacokinetics of 50 mg/kg saquinavir 3 times a day (tid) alone versus 33 mg/kg saquinavir tid plus 30 mg/kg nelfinavir tid was assessed after single-dose administration and after short- and long-term administration. The single-dose pharmacokinetics of fixed (1200 mg) versus unrestricted weight-adjusted dosing (50 mg/kg) was also investigated. Results: Saquinavir as the sole protease inhibitor resulted in lower saquinavir exposure in children (steady-state geometric mean area under the concentration-time curve from time zero to 24 hours [AUC (0-24 h)], 5790 ng · h/ml; steady-state concentration 8 hours after drug administration [C8h,SS], 65 ng/ml) and adolescents [steady-state geometric mean AUC(0-24 h), 5914 ng · h/ml] than that reported in adults treated with 1200 mg tid [steady-state geometric mean AUC(0-24 h), 21,700 ng · h/ml; C8h,SS, 223 ng/ml]. This finding appeared to be attributable to markedly higher apparent oral clearance, potentially as a result of increased systemic clearance and reduced oral bioavailability. Nelfinavir combined with saquinavir reduced apparent oral clearance, increasing saquinavir exposure in children [steady-state geometric mean AUC(0-24 h), 11,070 ng · h/ml; C8h,SS, 380 ng/ml] to levels that approach those observed in adults. A significant correlation between average trough concentration and sustained viral load suppression was observed in children. The apparent threshold for maintaining viral load suppression was a mean trough saquinavir concentration above 200 ng/ml. Conclusions: The pharmacokinetics of saquinavir in children is different from that of adults, and administration of saquinavir alone will not give consistently efficacious plasma levels. The best way of improving saquinavir exposure in children is through combination therapy with other protease inhibitors that inhibit saquinavir metabolism.",
author = "Sibylle Grub and Patricia DeLora and Eric L{\"u}din and Frank Duff and Fletcher, {Courtney V} and Brundage, {Richard C.} and Kline, {Mark W.} and Calles, {Nancy R.} and Heidi Schwarzwald and Karin Jorga",
year = "2002",
month = "4",
day = "13",
doi = "10.1067/mcp.2002.121423",
language = "English (US)",
volume = "71",
pages = "122--130",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection

AU - Grub, Sibylle

AU - DeLora, Patricia

AU - Lüdin, Eric

AU - Duff, Frank

AU - Fletcher, Courtney V

AU - Brundage, Richard C.

AU - Kline, Mark W.

AU - Calles, Nancy R.

AU - Schwarzwald, Heidi

AU - Jorga, Karin

PY - 2002/4/13

Y1 - 2002/4/13

N2 - Objective: Our objective was to investigate the clinical pharmacologic characteristics of saquinavir given as a soft gelatin capsule, either alone or in combination with nelfinavir, to children and adolescents with human immunodeficiency virus infection. Methods: The pharmacokinetics of 50 mg/kg saquinavir 3 times a day (tid) alone versus 33 mg/kg saquinavir tid plus 30 mg/kg nelfinavir tid was assessed after single-dose administration and after short- and long-term administration. The single-dose pharmacokinetics of fixed (1200 mg) versus unrestricted weight-adjusted dosing (50 mg/kg) was also investigated. Results: Saquinavir as the sole protease inhibitor resulted in lower saquinavir exposure in children (steady-state geometric mean area under the concentration-time curve from time zero to 24 hours [AUC (0-24 h)], 5790 ng · h/ml; steady-state concentration 8 hours after drug administration [C8h,SS], 65 ng/ml) and adolescents [steady-state geometric mean AUC(0-24 h), 5914 ng · h/ml] than that reported in adults treated with 1200 mg tid [steady-state geometric mean AUC(0-24 h), 21,700 ng · h/ml; C8h,SS, 223 ng/ml]. This finding appeared to be attributable to markedly higher apparent oral clearance, potentially as a result of increased systemic clearance and reduced oral bioavailability. Nelfinavir combined with saquinavir reduced apparent oral clearance, increasing saquinavir exposure in children [steady-state geometric mean AUC(0-24 h), 11,070 ng · h/ml; C8h,SS, 380 ng/ml] to levels that approach those observed in adults. A significant correlation between average trough concentration and sustained viral load suppression was observed in children. The apparent threshold for maintaining viral load suppression was a mean trough saquinavir concentration above 200 ng/ml. Conclusions: The pharmacokinetics of saquinavir in children is different from that of adults, and administration of saquinavir alone will not give consistently efficacious plasma levels. The best way of improving saquinavir exposure in children is through combination therapy with other protease inhibitors that inhibit saquinavir metabolism.

AB - Objective: Our objective was to investigate the clinical pharmacologic characteristics of saquinavir given as a soft gelatin capsule, either alone or in combination with nelfinavir, to children and adolescents with human immunodeficiency virus infection. Methods: The pharmacokinetics of 50 mg/kg saquinavir 3 times a day (tid) alone versus 33 mg/kg saquinavir tid plus 30 mg/kg nelfinavir tid was assessed after single-dose administration and after short- and long-term administration. The single-dose pharmacokinetics of fixed (1200 mg) versus unrestricted weight-adjusted dosing (50 mg/kg) was also investigated. Results: Saquinavir as the sole protease inhibitor resulted in lower saquinavir exposure in children (steady-state geometric mean area under the concentration-time curve from time zero to 24 hours [AUC (0-24 h)], 5790 ng · h/ml; steady-state concentration 8 hours after drug administration [C8h,SS], 65 ng/ml) and adolescents [steady-state geometric mean AUC(0-24 h), 5914 ng · h/ml] than that reported in adults treated with 1200 mg tid [steady-state geometric mean AUC(0-24 h), 21,700 ng · h/ml; C8h,SS, 223 ng/ml]. This finding appeared to be attributable to markedly higher apparent oral clearance, potentially as a result of increased systemic clearance and reduced oral bioavailability. Nelfinavir combined with saquinavir reduced apparent oral clearance, increasing saquinavir exposure in children [steady-state geometric mean AUC(0-24 h), 11,070 ng · h/ml; C8h,SS, 380 ng/ml] to levels that approach those observed in adults. A significant correlation between average trough concentration and sustained viral load suppression was observed in children. The apparent threshold for maintaining viral load suppression was a mean trough saquinavir concentration above 200 ng/ml. Conclusions: The pharmacokinetics of saquinavir in children is different from that of adults, and administration of saquinavir alone will not give consistently efficacious plasma levels. The best way of improving saquinavir exposure in children is through combination therapy with other protease inhibitors that inhibit saquinavir metabolism.

UR - http://www.scopus.com/inward/record.url?scp=0036215227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036215227&partnerID=8YFLogxK

U2 - 10.1067/mcp.2002.121423

DO - 10.1067/mcp.2002.121423

M3 - Article

VL - 71

SP - 122

EP - 130

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -